Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

Related Articles by Review for PubMed (Select 11950689)

1.

RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.

Schoppet M, Preissner KT, Hofbauer LC.

Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):549-53. Review.

2.

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.

Kostenuik PJ, Shalhoub V.

Curr Pharm Des. 2001 May;7(8):613-35. Review.

PMID:
11375772
3.
4.

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Hofbauer LC, Heufelder AE.

J Mol Med (Berl). 2001 Jun;79(5-6):243-53. Review.

PMID:
11485016
5.
6.
7.

Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.

Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC.

Calcif Tissue Int. 2004 Jan;74(1):103-6. Epub 2003 Oct 6. Review.

PMID:
14523602
8.
9.

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.

Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D.

Cytokine Growth Factor Rev. 2004 Dec;15(6):457-75. Review.

PMID:
15561602
10.

Crystal structure of RANK ligand involved in bone metabolism.

Ito S, Hata T.

Vitam Horm. 2004;67:19-33. Review.

PMID:
15110169
11.

[Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].

Mochizuki S, Kiyokawa A, Nagayama Y.

Clin Calcium. 2005 Jan;15(1):35-42. Review. Japanese.

PMID:
15632471
12.

Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.

Hofbauer LC.

Eur J Endocrinol. 1999 Sep;141(3):195-210. Review. No abstract available.

13.

[Advances in ostheochlast biology: the osteoprotegerin-RANK ligand system].

Muñoz-Torres M, de la Higuera López-Frías M, Fernández García D.

Med Clin (Barc). 2004 Jan 24;122(2):75-7. Review. Spanish. Erratum in: Med Clin (Barc). 2004 Feb 28;122(7):258.

PMID:
14733862
14.

Bone destruction in arthritis.

Gravallese EM.

Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii84-6. Review.

15.

The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL.

J Bone Miner Res. 2000 Jan;15(1):2-12. Review.

PMID:
10646108
16.

Immune function of the decoy receptor osteoprotegerin.

Bengtsson AK, Ryan EJ.

Crit Rev Immunol. 2002;22(3):201-15. Review.

PMID:
12498383
17.

[Bone remodeling and mineral homeostasis].

Nakamura M, Udagawa N, Nakamura H.

Clin Calcium. 2006 Jan;16(1):46-53. Review. Japanese.

PMID:
16397350
18.

[Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].

Stajszczyk M.

Pol Arch Med Wewn. 2002 Sep;108(3):915-24. Review. Polish. No abstract available.

PMID:
12600190
19.

Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands.

Horowitz MC, Xi Y, Wilson K, Kacena MA.

Cytokine Growth Factor Rev. 2001 Mar;12(1):9-18. Review.

PMID:
11312114
20.

[Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].

Ferrer Cañabate J, Tovar I, Martínez P.

An Med Interna. 2002 Aug;19(8):385-88. Review. Spanish. No abstract available.

PMID:
12244784
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk